levodopa has been researched along with Age-Related Osteoporosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatani, M; Handa, K; Hosonuma, M; Inagaki, K; Ishikawa, K; Karakawa, A; Kiuchi, Y; Kiyohara, S; Negishi-Koga, T; Sakai, N; Takami, M; Tsuji, M; Yamakawa, T | 1 |
| Chun, S; Chung, SJ; Kim, BJ; Kim, GS; Kim, HK; Kim, MJ; Kim, SR; Koh, JM; Lee, MC; Lee, SH; Ryu, JS | 1 |
| Gnädinger, M; Kaelin-Lang, A; Mellinghoff, HU | 1 |
| Bloem, BR; Munneke, M; Petzinger, GM; Speelman, AD; van de Warrenburg, BP; van Nimwegen, M | 1 |
| Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K | 1 |
| Bilezikian, JP; Chan, FK; Kurland, ES; Rosen, CJ | 1 |
2 review(s) available for levodopa and Age-Related Osteoporosis
| Article | Year |
|---|---|
Parkinson's disease and the bones.
Topics: Accidental Falls; Antiparkinson Agents; Bone and Bones; Bone Density; Fractures, Bone; Humans; Levodopa; Osteoporosis; Parkinson Disease; Risk Assessment; Vitamin D | 2011 |
How might physical activity benefit patients with Parkinson disease?
Topics: Antiparkinson Agents; Cardiovascular Diseases; Cognition; Constipation; Depressive Disorder; Dopamine; Humans; Levodopa; Motor Activity; Muscle Fatigue; Osteoporosis; Parkinson Disease; Psychomotor Performance; Quality of Life; Sedentary Behavior; Sleep Wake Disorders | 2011 |
1 trial(s) available for levodopa and Age-Related Osteoporosis
| Article | Year |
|---|---|
Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I.
Topics: Adult; Aged; Arginine; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Levodopa; Male; Middle Aged; Osteoporosis; Secretory Rate; Stimulation, Chemical | 1998 |
3 other study(ies) available for levodopa and Age-Related Osteoporosis
| Article | Year |
|---|---|
Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson's disease model mice.
Topics: Animals; Antiparkinson Agents; Bone Diseases, Metabolic; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Female; Levodopa; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Osteoporosis; Parkinson Disease | 2019 |
Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bone and Bones; Bone Density; Causality; Cohort Studies; Comorbidity; Female; Fractures, Bone; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Osteoporosis; Prevalence; Risk Factors; Up-Regulation | 2010 |
RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Cohort Studies; Female; Follow-Up Studies; Fractures, Spontaneous; Hip Fractures; Homocysteine; Humans; Hyperhomocysteinemia; Immobilization; Incidence; Japan; Levodopa; Osteoporosis; Parkinson Disease; Proportional Hazards Models; Risk Factors | 2005 |